Source: Eur Respir J 2016; 48: 600-603
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Lopez-Campos Jose Luis, Márquez-Martín Eduardo, Casanova Ciro. Beta-blockers and COPD: the show must go on. Eur Respir J 2016; 48: 600-603

Member's Comments

No comment yet.

Related content which might interest you: Beta-blockers in COPD: time for reappraisal Source: Eur Respir J 2016; 48: 880-888 Year: 2016 Is the coprescription of Beta-blockers and Beta2-agonists justified in patients with coexisting COPD and CHF? Source: Annual Congress 2009 - Beta-blockers may now be beneficial in asthma and COPD Year: 2009 Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Corticosteroids and exacerbations of COPD Source: Annual Congress 2007 - Corticosteroids and respiratory failure Year: 2007 Using cardioselective beta-blockers in patients with cardiovascular diseases and COPD Source: Eur Respir J 2005; 26: Suppl. 49, 294s Year: 2005 Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 Exacerbations of COPD and treatment Source: International Congress 2018 – PG1 Asthma and chronic obstructive pulmonary disease Year: 2018 Cardiovascular medications and mortality in patients hospitalised with acute exacerbations of COPD Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Comorbidities in elderly smokers with COPD or CHF Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Statins and outcome of COPD patients after hospitalization for COPD exacerbations Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-severe COPD: A pooled analysis Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Long-acting bronchodilators in COPD: where are we now and where are we going? Source: Breathe 2014; 10:110-120 Year: 2014 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Predictors of coronary heart disease in patients with COPD Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Exacerbations of COPD Source: Eur Respir Rev, 27 (147) 170103; 10.1183/16000617.0103-2017 Year: 2018 Comorbidities – should we and how should we treat them in asthma and COPD? Source: International Congress 2014 – PG02 Current clinical problems in pulmonology Year: 2014 Antibiotics in COPD exacerbations: practice and evidence Source: Breathe 2009; 5: 299-301 Year: 2009